<DOC>
	<DOCNO>NCT01855711</DOCNO>
	<brief_summary>This study exploratory study aim ( ) obtain clinical experience GR68755 Japanese subject severe d-IBS explore feasibility next phase study ( ii ) obtain reference data endpoint dosage administration next phase study .</brief_summary>
	<brief_title>Safety Efficacy Study GR68755 ( Alosetron Hydrochloride ) Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome ( IBS )</brief_title>
	<detailed_description>The study objectives obtain clinical experience GR68755 1 mg QD Japanese female subject severe d-IBS frequent bowel urgency obtain exploratory efficacy safety data use reference endpoint dosage administration next phase clinical study Japan . After give write informed consent , subject undergo essential observation examination screen phase subject meet eligibility criterion enter treatment phase . When subject enter treatment phase , subject administer GR68755 1 mg tablet QD morning every day 28 day next day receive investigational product .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Alosetron</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : 1 . Disease treat : Has diagnose severe dIBS ( least 6 month dIBS symptom define Rome II Criteria ) , fail conventional IBS therapy . The following criterion ( 2. 3 . ) confirm end screening phase ( assign investigational product ) base record diary card . 2 . Meets ( 1 ) ( 2 ) 1week screen phase . ( 1 ) Has record symptom data least 6 day diary card screen phase . In case patient whose screen phase 5 day , record symptom data day ( 5 day ) diary card screening phase ( 2 ) An average stool consistency score record diary card screen phase &gt; =3.0 . Stool consistency score 1 . = hard 2 . = hard 3 . = form 4 . = loose 5 . = watery 3.Meets follow ( 1 ) ( 2 ) : ( 1 ) Average `` severity abdominal pain discomfort '' score record diary card screen phase &gt; =1.0 ( 2 ) Has frequent `` bowel urgency '' ( urgency &gt; = 50 % day screen phase ) Severity pain discomfort score 1 . = mild 2 . = moderate 3 . = intense 4 . = severe However , subject experience abdominal pain discomfort , score zero ( 0 ) . 4.Age : Is 2064 year age 5.Sex : Female 6.Type subject : Outpatient 7.Is ambulatory ( depend wheelchair mobility ) 8.Is pregnant , lactating , intend become pregnant study period . Females nonchild bear potential allow participate study one follow criterion meet : Sterilization ( via hysterectomy bilateral tubal ligation ) Postmenopausal ( define one year without menses ) Females childbearing potential may also enrol subject demonstrate negative serum Î²hCG test screening , agree practice contraception throughout study . The following method contraception acceptable . Oral birth control pill administer least one monthly cycle prior investigational product administration An IUD ( intrauterine contraceptive device ) Complete abstinence intercourse two week prior investigational product administration throughout study period . 9.Has normal result follow test symptom remain stable , accord subject 's age , within two year screen visit IBS symptom develop . &lt; 50 year age : sigmoidoscopy , sigmoidoscopy plus barium enema , colonoscopy . = &gt; 50 year age : sigmoidoscopy plus barium enema , colonoscopy . If subject perform flexible sigmoidoscopy , flexible sigmoidoscopy plus barium enema , colonoscopy development IBS within 2 year screen visit , appropriate procedure perform judge eligible study procedure window . After complete test , least three day interval provide enter treatment phase . However , maximum interval completion test entry treatment phase 7 day . If subject eligible base data record diary card day test conduct , subject withdraw study prior test . 10.Is able give write informed consent . A subject eligible inclusion study follow criterion apply : 1 . Does severe dIBS 2 . Has current evidence history chronic severe constipation , history sequelae constipation . 3 . Is currently constipate report stool three consecutive day screen phase . 4 . Has evidence bloody diarrhea abdominal pain lower gastrointestinal hemorrhage . 5 . Has current evidence uncontrollable cardiovascular , renal , hepatic , pulmonary , endocrine , metabolic , hematologic , digestive condition ( exclude IBS ) . 6 . Has evidence biochemical structural abnormality digestive tract . These condition include evidence history follow : Ischemic colitis Impaired intestinal circulation gastrointestinal perforation gastrointestinal obstruction and/or stricture diverticulitis Inflammatory bowel disease ( Crohn 's disease ulcerative colitis ) Microscopic colitis ( lymphocytic colitis , collagenous colitis ) , celiac sprue Laxative abuse ( clinical judgement investigator/subinvestigator ) melanosis coli . Gastroparesis GI malignancy Carcinoid syndrome Amyloidosis Chronic pancreatitis Abdominal adhesion Toxic megacolon Acute proctitis Fecal impaction Symptomatic cholelithiasis 7 . Has perform gastrointestinal surgery ( except six month postsurgery appendectomy , cholecystectomy , benign polypectomy , fundoplication ( gas bloat ) , hiatal hernia repair ; three month postsurgery herniorrhaphy without bowel resection ) 8 . Has history thrombophlebitis hypercoagulable state . 9 . Has diagnose psychiatric disorder require hospitalization and/or involve suicide attempt ( however , subject history severe psychiatric disorder within past two year , subject may enter study symptom control stable dose medicine least six month prior screen visit ) 10 . Has history alcohol and/or drug abuse within past two year . 11 . Exhibits evidence hepatic dysfunction ( AST [ GOP ] ALT [ GPT ] value &gt; 2.5 time upper limit normal alkaline phosphatase serum bilirubin value &gt; 2.0 time upper limit normal ) 12 . Exhibits evidence renal impairment ( serum creatinine value &gt; 2.0 mg/dl ) 13 . Exhibits abnormal serum thyroidstimulating hormone ( TSH ) ( TSH value exceed limit normal clinical laboratory ) . 14 . Has current evidence , treat malignancy within past five year ( localize basal cell , squamous cell skin cancer cancer situ resect ) . 15 . Has use GR68755 tablet participate clinical study 5HT3 antagonist IBS patient within three year prior screen visit . 16 . Has enrol clinical study within four month prior screen visit . 17 . Has use prohibit concomitant medicine within seven day prior screen visit . However loperamin hydrochloride butylscopolamine bromide may take 24 hour start screening period . 18 . Has use permit concomitant medication within 30 day prior screen visit adjust dose . 19 . Is hypersensitive 5HT3 antagonist . 20 . Is pregnant breastfeeding . 21 . Is eligible participate study opinion investigator/subinvestigator .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Alosetron hydrochloride</keyword>
	<keyword>Global Improvement Scale ( GIS )</keyword>
	<keyword>Diarrhea-predominant IBS</keyword>
</DOC>